Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
KPV reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
KPV is a synthetic tripeptide; the anti-inflammatory pharmacophore of alpha-msh of 3 amino acids. Sequence: Lys-Pro-Val (KPV). The C-terminal fragment of alpha-melanocyte-stimulating hormone.
Reported to undergo PepT1-mediated colon-selective uptake, to block NF-κB nuclear translocation, and to behave as an IL-1β antagonist. Vectra makes no claim as to mechanism or effect.
Identified in the late 1980s by Lipton's group at NIH. A multicentre Phase IIa randomised, double-blind, placebo-controlled trial (Kucharzik et al., 2017) studied the D-isomer K(D)PT in ulcerative colitis. First described by Lipton's group at NIH (Late 1980s).
Studied in NF-κB signalling, and in preclinical models of colitis, dermatitis and oral mucositis. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Health utility scored 4 of 10, with a conditional verdict: 3 of 5 for the oral D-isomer in ulcerative colitis, 2 of 5 for preclinical colitis, dermatitis and oral mucositis. Note what the Phase IIa trial actually studied: K(D)PT, the D-isomer, not KPV. The evidence that exists is for a related but distinct molecule.
Generally well tolerated, with mild gastrointestinal upset in roughly 3–5% of oral users. Contraindicated in active malignancy and in pregnancy or lactation.
Lyophilised powder is stable in a freezer at -20°C for up to two years, or refrigerated at 2–8°C for three to six months.
Our sources carry no CAS number, molecular formula, or molecular weight for KPV.
Not approved. Placed on the FDA 503A Category 2 list since 2023, prohibiting compounding by 503A and 503B facilities. Note that FDA's advisory committee recommended KPV for the 503A Bulks List in July 2026, by 8–6 with one abstention — a recommendation, not an approval. Not specifically listed by WADA, though the S0 catch-all applies. No therapeutic, preventive, or diagnostic claims are made or implied.
Not approved as a medicinal product in any jurisdiction. Current FDA position: 503A Category 2. Awaiting FDA determination and rulemaking following the July 2026 advisory recommendation. Vectra supplies this material as a research-use-only reference material. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes. The FDA Pharmacy Compounding Advisory Committee considered it at its July 23–24, 2026 meeting. The committee's vote was: recommended (8–6, 1 abstention, July 23). The votes are advisory and not binding. FDA makes the final determination, and inclusion requires proposed and final rulemaking, with formal approval by the Secretary of Health and Human Services. None of the six is legal to compound on the strength of the vote alone; reporting at the time put the earliest realistic timeline at roughly twelve months.
FDA reviewers concluded the substance did not meet the agency's four-part standard. FDA career reviewers published briefing documents recommending against all seven substances, concluding that none met the agency's four-part evidentiary standard.
Category 2 is not a ban and not a scheduling action. It describes where a nominated substance sits in an unfinished evaluation process. An interim FDA designation for nominated bulk drug substances for which the agency identified potential significant safety risks. Substances in Category 2 sit outside FDA's Category 1 enforcement-discretion policy.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.